187 related articles for article (PubMed ID: 20305131)
1. Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Normanno N; Tejpar S; Ciardiello F
J Natl Cancer Inst; 2010 Apr; 102(8):573; author reply 573-5. PubMed ID: 20305131
[No Abstract] [Full Text] [Related]
2. EGFR antibodies in colorectal cancer: where do they belong?
Grothey A
J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
[No Abstract] [Full Text] [Related]
3. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
4. Metastatic colorectal cancer: is there one standard approach?
Saltz LB
Oncology (Williston Park); 2005 Aug; 19(9):1147-54; discussion 1154, 1157-8, 1160. PubMed ID: 16255132
[TBL] [Abstract][Full Text] [Related]
5. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
6. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
[No Abstract] [Full Text] [Related]
7. Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Peeters M; Price T
Cancer Treat Rev; 2012 Aug; 38(5):397-406. PubMed ID: 21899955
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Loupakis F; Di Maio M; Falcone A
N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445032
[No Abstract] [Full Text] [Related]
9. A novel K-ras mutation in colorectal cancer. A case report and literature review.
Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
[TBL] [Abstract][Full Text] [Related]
11. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
Chu E
Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
[No Abstract] [Full Text] [Related]
12. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
13. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
14. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
[TBL] [Abstract][Full Text] [Related]
15. First-line therapeutic strategies in metastatic colorectal cancer.
Davies JM; Goldberg RM
Oncology (Williston Park); 2008 Nov; 22(13):1470-9. PubMed ID: 19133603
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in colorectal cancer.
Sharieff W
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
18. [Validation study of KRAS mutation in colorectal cancer].
Kopper L; Tímár J
Magy Onkol; 2009 Dec; 53(4):361-6. PubMed ID: 20071308
[TBL] [Abstract][Full Text] [Related]
19. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Pietrantonio F; Garassino MC; Torri V; de Braud F
Ann Oncol; 2012 Oct; 23(10):2771-2772. PubMed ID: 22875835
[No Abstract] [Full Text] [Related]
20. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]